Wednesday, 08 Apr 2020

You are here

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

This study was a systematic review and meta-analysis of 33 case series, with a total of 7232 knee replacements. Twenty six case series looked at total replacement, whereas seven reported survival of unicompartmental replacement. Data from the Australian and Finnish national registries were used, with a total of 299 291 total replacements and 7714 unicompartmental replacements.

The most reliable data came from the national registries showing that for total knee replacements:

  • At 15 years, 93% were intact (95% confidence interval 92.8 to 93.1)
  • At 20 years, 90.1% of replacements survived (89.7 to 90.4)
  • At 25 years, 82.3% of replacements were still intact 

For unicompartmental knee replacements:

  • At 15 years, 76.5% were still intact (75.2 to 77.7)
  • At 20 years, 71.6% survived (69.6 to 73.6)
  • At 25 years, 69.8% were still intact (67.6 to 72.1)

Since at least 80% of total replacements will last for 25 years, it is possible that more candidates may be offered surgery at a younger age.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.

Diabetes in OA: Pain Is Worse

Among patients with knee osteoarthritis (OA), pain was greater for those with coexisting diabetes mellitus (DM), and this association was independent of obesity and radiographic severity, European researchers found. 

JAK Inhibitors Stimulate Osteoblasts

Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).

JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling RA inflammation and other clinical features.

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.